Ovarian cancer remains a highly lethal disease. In devel- oped countries, ovarian cancer accounts for more deaths than all other gynecological malignancies combined; an estimated 22,430 new cases and 15,280 deaths occurred in 2007 (Can- cer Facts & Figures 2007). As the result of advances in sur- gical management and chemotherapeutic options over the last three decades, the median survival times for ovarian cancer patients has improved. However, overall survival has not been significantly changed. In addition, most patients present with advanced disease for which highly effective curative therapy is currently unavailable. The epithelial tu- mors of the ovary, which account for 90% of malignant ovarian tumors, are further divided into histological sub- groups with different malignant potential endometrioid, mucinous, serous, clear cell and undifferentiated carcinomas. In follow-up studies, mucinous and endometrioid carcinomas have a less aggressive behavior and a better overall survival than serous tumors. A characteristic of serous, mucinous and endometrioid ovarian carcinomas is the low malignant po- tential (LMP), or in the case of borderline tumors, a low risk of invasion.

The molecular pathology of ovarian carcinomas is het- erogeneous and involves various putative precursor lesions and multiple pathways of development. The most common subtype, high-grade serous carcinoma, is characterized by p53 mutations, and BRCA1 and/or BRCA2 dysfunction. It most likely arises from epithelium within inclusion cysts or from the surface of the ovary. Dysregulation of cell cycle control, in particular G₁-S-phase transition, is implicated in the pathogenesis of most human cancers, including epithelial ovarian cancer (EOC). However, the prognostic significance of aberrant cell cycle gene expression in EOC remains mostly unclear. During the G₁-S transition, the cy- clinE/CDK2 and cyclinD/CDK4 complexes promote pro- gression and are each inhibited by the associated CDK in- hibitor p27^KIP1. If DNA damage occurs, p53 accumulates in the cells and induces the p21-mediated inhibition of cy- clinD/CDK. The transition to S phase is triggered by the activation of the cyclinD/CDK complex, which phosphory- lates the retinoblastoma protein pRb, a known cell prolifera-tion regulator.

The members of the INK4 family, comprising p16 and p15, exert their inhibitory activity by binding to the CDK4 and CDK6 kinases and preventing their association with D- type cyclins. In contrast to G₁ regulators, less is known about the genes which regulate the S, G₂ and M phases of the cell cy- cle, such as cyclin A- and cyclin B-kinase complexes and their inhibitors. The significance of cell-cycle regulatory genes in carcinogenesis is underlined by the fact that most of them have been identified as proto-oncogenes or tumor sup- pressor genes.

Expression of cell cycle markers has recently been linked to tumor behavior and response to treatment. Hopefully, a better understanding of the molecular mechanisms underly- ing the tumorigenic process of ovarian carcinoma will lead to earlier diagnosis, novel therapies and ultimately better outcomes.

Ovarian serous carcinoma is the most common and lethal type of ovarian cancer and its molecular etiology remains poorly understood. The expression of selected genes from the pRb pathway that regulates G₁-S-phase progression, in-cluding cyclin D1, p16^INK4A, cyclin E, p27^KIP1, p21^WAF1/CIP1, and p53, was examined in a consecutive series of 134 serous epithelial ovarian cancers (EOC) using immunohistochemis- try. Molecular markers predictive of reduced overall survival in univariate analysis were overexpression of cyclin D1 (P = 0.03) and p53 (P = 0.03) and reduced expression of p27^KIP1 (P= 0.05) and p21^WAF1/CIP1 (P = 0.02), with the latter three also being prognostic for a shorter progression-free interval. In addition, patients displaying overexpression of p53 with concurrent loss of p21^WAF1/CIP1 had a significantly shorter overall (P=0.0008) and progression-free survival (P=0.0001). On multivariate analysis, overexpression of cyclin D1 and combined loss of p21^WAF1/CIP1 in the presence of p53 overex- pression were independent predictors of overall survival. Similarly, the combination of p21^WAF1/CIP1 loss and p53 over- expression was independently predictive of a shorter pro- gression-free interval. Overexpression of p53 and cyclin E and reduced expression of p27^KIP1 and p21^WAF1/CIP1 were sig- nificantly associated with increasing tumor grade. This study confirms that dysregulation of cell cycle genes is common in EOC, and that aberrant expression of critical cell cycle regu- latory proteins can predict patient outcome in serous EOC [1].

Buchynska et al. have shown that serous ovarian carci- nomas are characterized by high proliferative activity (PI Ki- 67 = 30.0 +/- 0.3%), p53 and p16^INK4A overexpression and low expression of p21^WAF1/CIP1. The association between ex-pression of these markers and ovarian tumor grade was de- fined: the maximal level of Ki-67, p53 and p16^INK4A and minimal of p21^WAF1/CIP1 expression were observed in G3 tu- mors. So, low p21^WAF1/CIP1 expression combined with p16^INK4A overexpression is considered to be a factor for a poor prognosis in serous ovarian cancer [2].

Reduced expression of the cyclin-dependent kinase in- hibitor p27^KIP1 has been reported to be associated with poor prognosis in several human cancers. In serous ovarian can- cers, positive p27^KIP1 staining rate was significantly higher in early stage than that in advanced stage diseases (p=0.030, Fisher's exact test). Log-rank testing showed that negative p27^KIP1 expression significantly correlates with poor survival in serous ovarian cancer patients (p=0.041). These results suggest that the underexpression of p27^KIP1 caused by post- translational mechanism may contribute to the development and progression and result in poor prognosis of serous ovar- ian cancers [3].

It is well known that somatic mutation of p53 represents the most common molecular genetic alteration occurring in epithelial ovarian carcinoma. Inactivation of p53 was de- tected in 30-80% of ovarian carcinoma [4, 5].

Although p53 overexpression was a common feature of both mucinous and serous borderline tumors, p21^WAF1/CIP1 overexpression appeared specific to serous tumors [6].

Statistical analyses showed a significantly higher expres- sion of p53 in histologically high-grade tumors (grades 2 and 3), mainly of the serous subtyp. A statistical tendency toward higher expression of p53 in older patients (P= 0.08) was also observed. p53 is associated with serous carcinoma, loss of differentiation, and older patients. These results are in keep- ing with different pathogenetic pathways in subtypes of ovarian carcinoma, prompting the search for new strategies of prevention and treatment [7].

The frequency of p53 mutation in early-stage ovarian carcinomas of serous histology is comparable to that re- ported for advanced-stage tumors, and it is therefore likely to occur early in the progression of the most common his- tological variant of ovarian carcinoma [8]. For invasive car- cinomas, the rate of mutation and expression increases with increasing tumor grade and stage, and is more common in tumors of serous histology [9]. Palazzo et al. demonstrated that coexpression of p21^WAF1/CIP1 and MDM2 characterizes serous borderline tumors of the ovary and their implants, which suggests that these cell cycle control proteins are im- portant in these tumors and may be related to tumor progres- sion. Low expression of p53 protein in serous borderline tumors might be in part mediated by MDM2. This suggests that the p53 pathway is intact in most of these tumors, in contrast with carcinomas, in which high expression of p53 has been related to mutations of this gene [10].

Mucinous carcinoma of the ovary accounts for 7% to 14% of all primary EOC [11]. Distinction of primary ovarian epithelial tumors from metastatic adenocarcinomas is chal- lenging for tumors exhibiting mucinous, endometrioid, or mixed endometrioid/mucinous differentiation. Metastatic carcinomas with these types of differentiation can be derived from several sites, including the gastrointestinal tract and the uterus. Most endocervical adenocarcinomas exhibit muci- nous and/or endometrioid differentiation; they infrequently metastasize to the ovaries but may simulate primary ovarian tumors (both borderline and carcinoma). Most are high-risk human papillomavirus (HPV)-related and demonstrate dif- fuse p16 over-expression due to complex molecular mecha- nisms by which high-risk HPV transforming proteins interact with cell cycle regulatory proteins. Vang et al. evaluated this expression pattern for identifying metastatic endocervical adenocarcinomas in the ovaries among primary ovarian tu- mors and other metastatic adenocarcinomas having muci- nous and/or endometrioid/endometrioidlike differentiation. Immunohistochemical expression of p16 was assessed in 195 tumors, including 102 primary ovarian tumors (51 mucinous, 47 endometrioid, and 4 mixed mucinous-endometrioid tu- mors), 82 metastatic adenocarcinomas of known primary sites (colorectum: 34, endocervix: 19, pancreaticobiliary tract: 17, appendix: 7, stomach: 5), 11 metastatic adenocarci- nomas of unknown origin, and 4 adenocarcinomas of uncer- tain origin. Mean and median p16 expression values for HPV-positive endocervical adenocarcinomas were substan- tially higher than those for primary ovarian mucinous and endometrioid tumors, HPV-unrelated endocervical adenocar- cinomas, metastatic adenocarcinomas of unknown origin, and adenocarcinomas of uncertain (primary ovarian vs. me- tastatic) origin. Only the 15 HPV-positive endocervical ade- nocarcinomas and 6 other tumors had values of 80% or greater. Diffuse (>75% positive tumor cells), moderate to strong p16 expression is a sensitive (100%) and specific (97%) marker for identifying HPV-related endocervical ade- nocarcinomas metastatic to the ovary among the primary ovarian tumors and metastatic adenocarcinomas from other sites that are in the differential diagnosis of ovarian tumors having mucinous and/or endometrioid/endometrioidlike dif- ferentiation. p16 is useful as part of a panel of immunohisto- chemical markers for distinguishing primary ovarian tumors from metastases and, when diffusely positive, can suggest the cervix as a potential primary site for metastatic adenocar- cinomas of unknown origin [12].

Patients with advanced mucinous EOC have a poorer response to platinum-based first-line chemotherapy com- pared with patients with other histologicsubtypes of EOC, and their survival is worse. Specific alternative therapeutic approaches should be sought for this group of patients,per- haps involving fluorouracil-based chemotherapy [13].

Plisiecka-Halasa et al. evaluated the clinical and biologi- cal significance of p21^WAF1/CIP1, p27^KIP1, c-myc, p53 and Ki67 expressions in ovarian cancer patients. Immunohisto- chemical analysis was performed on 204 ovarian carcinomas of International Federation of Gynecology and Obstetrics (FIGO) stage IIB to IV treated with platinum-based chemo- therapy. Endometrioid and clear cell carcinomas differed from other carcinomas by having a low incidence of p53 accumulation, a high incidence of c-myc overexpression (70%) and a low median Ki67 labeling index (LI) (all with P <0.001). The authors have shown an independent predictive value of p21^WAF1/CIP1 LI in ovarian carcinoma patients. The prognostic value of p21^WAF1/CIP1 and p21^WAF1/CIP1 plus p27^KIP1 LI was determined by p53(-) status. A high frequency of c- myc overexpression in endometrioid and clear cell carcino- mas may suggest its role in the development of these tumor types [14]. High-level p16 expression was observed in se- rous and endometrioid phenotypes, with a positive relation to high levels of both cell proliferation and p53 abnormalities. None of 131 cases analyzed by Saegusa et al. showed a methylation status of the p16 gene promoter [15]. Two dif-ferent studies also revealed no evidence of methylation and low levels of mutations [16] [17]. However there are some data supporting p16 promoter hypermethylation as a mecha-nism underlying the downregulation of the gene. Milde-Langosch et al. found hypermethylation in 12/19 negative cases, most of them mucinous and endometrioid carcinomas [18]. Alterations in p15 were observed in serous, endo-metrioid and clear cell but not in mucinous carcinomas, sug-gesting that inactivation of p15 may be the histological type-specific event in ovarian tumorigenesis [19].

Ovarian clear cell carcinoma revealed significantly in-creased cyclin E associated with an increase in p21^WAF1/CIP1, compared to the other histological subtypes [20].

Clear cell carcinoma revealed such trends as low expres- sion of both p53 and cyclin A and significantly increased expression of both p21^WAF1/CIP1 and cyclin E compared with the other histologic subtypes. In all ovarian carcinomas, a very strong positive correlation between p53 positive stain-ing and cyclin A positive staining and a weak positive corre-lation between p21^WAF1/CIP1 positive staining and cyclin E positive staining were recognized at the level of expression of cell cycle regulatory molecules. Clinical stage was the only independent predictive factor for the survival of the patients. Among ovarian adenocarcinomas, clear cell carci-noma exhibits a unique pattern of expression of cell cycle regulatory molecules, though in this study the survival did not correlate with histologic subtype, only with clinical stage [20].

Cyclin E expression is significantly higher in clear cell carcinoma than in serous carcinoma and is significantly re- lated with p53 positivity [21].

Akahane et al. demonstrated that some genetic altera- tions, which induce p53 mutations in endometriosis, may affect malignant transformation of endometriosis into ovar- ian clear cell carcinoma [22].

The molecular changes in undifferentiated carcinomas of the ovary remain largely unknown [23].

In a recent study carried out by Rosen et al. overexpres- sion of cyclin E was found in 63.2% of the 405 primary ovarian carcinomas analyzed and was associated with clear cell, undifferentiated, and serous carcinoma (P < or = .001), high-grade tumors (P < or = .001), late-stage disease (P = .002), age older than 60 years at the time of diagnosis (P = .04), and suboptimal cytoreduction (P = .001). A high per- centage of cyclin E-expressing cells was associated with a poor outcome in univariate and in multivariate analyses. In addition, cyclin E levels also reduced survival in the late- stage disease group and in patients who underwent subopti- mal debulking. Cyclin E was identified as an independent prognostic factor in patients with ovarian carcinoma. The accumulation of cyclin E protein may be a late event in tu- morigenesis and may contribute to disease progression in these patients [24]

The identified molecular changes in epithelial ovarian cancers can facilitate the rational development of new diag- nostic modalities and tailored therapies for these malignan- cies. Most of the G₁-S regulators play an important role in ovarian cancer due to the fact that they control the G₁-S tran- sition, a crucial step in cell cycle control. Cyclin E is a key regulator of the G₁-S transition. Abnormalities in cyclin E expression have been related to survival in a variety of can- cers. Cyclin E plays an important role in ovarian carcino- genesis of clear cell, undifferentiated, and serous carcinomas and its overexpression may be an indicator of a poor progno- sis. Cyclin E expression is significantly higher in clear cell carcinoma than in serous carcinoma and is significantly re- lated with p53 positivity. Overexpression of cyclin E was also found to be associated with undifferentiated carcinomas of the ovary. The actual mutation of p53 is the most common molecular alteration occurring in both early-stage and inva- sive ovarian carcinomas, especially in those of serous histol- ogy, and confers resistance to chemotherapy and lead to shortened overall survival. Epithelial ovarian tumors show- ing p53 alterations are significantly less sensitive to chemo- therapy and more aggressive than those with functional p53 and overall survival is shortened in patients with p53 muta- tions [25, 26]. In serous carcinomas the combination of p21^WAF1/CIP1 loss and p53 overexpression was independently predictive of a shorter progression-free interval. Coexpres- sion of p21^WAF1/CIP1 and MDM2 characterizes serous border- line tumors of the ovary and their implants, which suggests that these cell cycle control proteins are important in these tumors and may be related to tumor progression. Low p21^WAF1/CIP1 expression combined with p16 overexpression is considered to be the indicator for a poor prognosis in serous ovarian cancer.

Mucinous and endometrioid carcinomas are largely char- acterized by p16 downregulation and the gene promoter hypermethylation. Lack of p16 is associated with p53 wt (wild type) and is typical of mucinous and endometrioid tumors. Little is known about the role of p15 in ovarian carcinomas. No mutations have been detected. Its inactivation may be the histological type-specific event in ovarian tumorigenesis. Alterations in p15 gene occur in serous, endometrioid and clear cell carcinomas but not in mucinous carcinomas. There are also a number of studies reporting no correlation between the expression of cell cycle genes and the different histotypes of ovarian carcinoma.

In fact, cyclin D1 and c-Myc which are key participants in the cell-cycle pathway are frequently overexpressed in epithelial ovarian carcinomas, but they are not correlated with a particular histologic subtype [27] and p27^KIP1 subcel- lular location in the cytoplasmwas independently associated with poorer survival among womenwith ovarian carcinoma, particularly for those with late-stagedisease and regardless of tumor histotype [28].

The described abnormalities of cell cycle regulators in ovarian carcinomas (Fig. 1) suggest that most of the cell cy- cle regulatory genes play a crucial role in ovarian carcinoma tumorigenesis and/or development. The main goal in cancer therapy remains an early diagnosis of the disease, and some of the cell cycle genes described could be useful markers for achieving this goal, and therefore more targeted therapies.

Fig. (1) Schematic model of cell cycle regulator genes involved in carcinogenesis of the different histotypes in epithelial ovarian cancer. The question mark in the undifferentiated tumor section underlines that the role of cell cycle genes in this histotype of ovarian cancer is largely unknown.